{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:49:56Z","timestamp":1793861396443,"version":"4.6.1"},"reference-count":93,"publisher":"American Association for Cancer Research (AACR)","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["WA 4608\/1-2"],"award-info":[{"award-number":["WA 4608\/1-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["CRC1479 Project ID 441891347-P03"],"award-info":[{"award-number":["CRC1479 Project ID 441891347-P03"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["CRC\/TRR167-Project ID 259373024-Z01"],"award-info":[{"award-number":["CRC\/TRR167-Project ID 259373024-Z01"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["CRC 1160-Project ID 256073931-Z02"],"award-info":[{"award-number":["CRC 1160-Project ID 256073931-Z02"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["CRC1479 Project ID 441891347-S1"],"award-info":[{"award-number":["CRC1479 Project ID 441891347-S1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["EXC2180 390900677"],"award-info":[{"award-number":["EXC2180 390900677"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["CIBSS &#x2013"],"award-info":[{"award-number":["CIBSS &#x2013"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["EXC 2189 project ID 390939984"],"award-info":[{"award-number":["EXC 2189 project ID 390939984"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002347","name":"Federal Ministry of Education and Research","doi-asserted-by":"crossref","award":["03ZU1111LB"],"award-info":[{"award-number":["03ZU1111LB"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002347","name":"Federal Ministry of Education and Research","doi-asserted-by":"crossref","award":["MIRACUM-FKZ 01ZZ1801B and PM4Onco-FKZ 01ZZ2322A"],"award-info":[{"award-number":["MIRACUM-FKZ 01ZZ1801B and PM4Onco-FKZ 01ZZ2322A"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012353","name":"German Cancer Consortium","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012353","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ernst Jung Prize for Medicine"},{"name":"Landesforschungspreis of Baden-W&#x00FC;rttemberg"},{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"crossref","award":["2016.177.3"],"award-info":[{"award-number":["2016.177.3"]}],"id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Jose Carreras Leuk&#x00E4;mie Stiftung","award":["DJCLS 05 R\/2017"],"award-info":[{"award-number":["DJCLS 05 R\/2017"]}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"crossref","award":["70114948"],"award-info":[{"award-number":["70114948"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"crossref","award":["310030_179239"],"award-info":[{"award-number":["310030_179239"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"crossref"}]},{"name":"European Research Council","award":["HemStem Consolidator Grant"],"award-info":[{"award-number":["HemStem Consolidator Grant"]}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"crossref","award":["2019_A74"],"award-info":[{"award-number":["2019_A74"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fort&#x00FC;ne Programm of the University of T&#x00FC;bingen","award":["2451-0-0"],"award-info":[{"award-number":["2451-0-0"]}]},{"name":"Fort&#x00FC;ne Program of the University of T&#x00FC;bingen","award":["2581-0-0"],"award-info":[{"award-number":["2581-0-0"]}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Therapy-resistant leukemia stem and progenitor cells (LSC) are a main cause of acute myeloid leukemia (AML) relapse. LSC-targeting therapies may thus improve outcome of patients with AML. Here we demonstrate that LSCs present HLA-restricted antigens that induce T-cell responses allowing for immune surveillance of AML. Using a mass spectrometry\u2013based immunopeptidomics approach, we characterized the antigenic landscape of patient LSCs and identified AML- and AML\/LSC-associated HLA-presented antigens absent from normal tissues comprising nonmutated peptides, cryptic neoepitopes, and neoepitopes of common AML driver mutations of NPM1 and IDH2. Functional relevance of shared AML\/LSC antigens is illustrated by presence of their cognizant memory T cells in patients. Antigen-specific T-cell recognition and HLA class II immunopeptidome diversity correlated with clinical outcome. Together, these antigens shared among AML and LSCs represent prime targets for T cell\u2013based therapies with potential of eliminating residual LSCs in patients with AML.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>The elimination of therapy-resistant leukemia stem and progenitor cells (LSC) remains a major challenge in the treatment of AML. This study identifies and functionally validates LSC-associated HLA class I and HLA class II\u2013presented antigens, paving the way to the development of LSC-directed T cell\u2013based immunotherapeutic approaches for patients with AML.<\/jats:p>\n                    <jats:p>See related commentary by Ritz, p. 430 .<\/jats:p>\n                    <jats:p>This article is featured in Selected Articles from This Issue, p. 419<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-23-0020","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T13:49:27Z","timestamp":1697550567000},"page":"468-489","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells"],"prefix":"10.1158","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8504-8481","authenticated-orcid":false,"given":"Annika","family":"Nelde","sequence":"first","affiliation":[{"name":"1Department of Peptide-Based Immunotherapy, University and University Hospital T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"2Institute for Cell Biology, Department of Immunology, University of T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"3Cluster of Excellence iFIT (EXC2180) \u201cImage-Guided and Functionally Instructed Tumor Therapies\u201d, University of T\u00fcbingen, T\u00fcbingen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6446-9425","authenticated-orcid":false,"given":"Heiko","family":"Schuster","sequence":"additional","affiliation":[{"name":"2Institute for Cell Biology, Department of Immunology, University of T\u00fcbingen, T\u00fcbingen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7305-8620","authenticated-orcid":false,"given":"Jonas S.","family":"Heitmann","sequence":"additional","affiliation":[{"name":"3Cluster of Excellence iFIT (EXC2180) \u201cImage-Guided and Functionally Instructed Tumor Therapies\u201d, University of T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"4Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital T\u00fcbingen, T\u00fcbingen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3731-2385","authenticated-orcid":false,"given":"Jens","family":"Bauer","sequence":"additional","affiliation":[{"name":"1Department of Peptide-Based Immunotherapy, University and University Hospital T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"2Institute for Cell Biology, Department of Immunology, University of T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"3Cluster of Excellence iFIT (EXC2180) \u201cImage-Guided and Functionally Instructed Tumor Therapies\u201d, University of T\u00fcbingen, T\u00fcbingen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2197-8740","authenticated-orcid":false,"given":"Yacine","family":"Maringer","sequence":"additional","affiliation":[{"name":"1Department of Peptide-Based Immunotherapy, University and University Hospital T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"2Institute for Cell Biology, Department of Immunology, University of T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"3Cluster of Excellence iFIT (EXC2180) \u201cImage-Guided and Functionally Instructed Tumor Therapies\u201d, University of T\u00fcbingen, T\u00fcbingen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1482-2062","authenticated-orcid":false,"given":"Melissa","family":"Zwick","sequence":"additional","affiliation":[{"name":"5Department of Medicine I, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens-Peter","family":"Volkmer","sequence":"additional","affiliation":[{"name":"6Institute for Stem Cell Biology and Regenerative Medicine and the Ludwig Cancer Center, Stanford University School of Medicine, Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4654-8130","authenticated-orcid":false,"given":"James Y.","family":"Chen","sequence":"additional","affiliation":[{"name":"6Institute for Stem Cell Biology and Regenerative Medicine and the Ludwig Cancer Center, Stanford University School of Medicine, Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3794-5003","authenticated-orcid":false,"given":"Anna M. Paczulla","family":"Stanger","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"8Department of Biomedicine, University of Basel and University Hospital Basel, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8611-3415","authenticated-orcid":false,"given":"Ariane","family":"Lehmann","sequence":"additional","affiliation":[{"name":"9Faculty of Medicine, Medical Center, Institute of Medical Bioinformatics and Systems Medicine (IBSM), University of Freiburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4670-3951","authenticated-orcid":false,"given":"Bismark","family":"Appiah","sequence":"additional","affiliation":[{"name":"9Faculty of Medicine, Medical Center, Institute of Medical Bioinformatics and Systems Medicine (IBSM), University of Freiburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2920-3894","authenticated-orcid":false,"given":"Melanie","family":"M\u00e4rklin","sequence":"additional","affiliation":[{"name":"3Cluster of Excellence iFIT (EXC2180) \u201cImage-Guided and Functionally Instructed Tumor Therapies\u201d, University of T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"4Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital T\u00fcbingen, T\u00fcbingen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0943-031X","authenticated-orcid":false,"given":"Elke","family":"R\u00fccker-Braun","sequence":"additional","affiliation":[{"name":"10Department of Medicine I, University Hospital of Dresden, Dresden, Germany."},{"name":"11Center for Regenerative Therapies Dresden, Technische Universit\u00e4t Dresden, Dresden, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6719-1847","authenticated-orcid":false,"given":"Helmut R.","family":"Salih","sequence":"additional","affiliation":[{"name":"3Cluster of Excellence iFIT (EXC2180) \u201cImage-Guided and Functionally Instructed Tumor Therapies\u201d, University of T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"4Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital T\u00fcbingen, T\u00fcbingen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7283-9778","authenticated-orcid":false,"given":"Malte","family":"Roerden","sequence":"additional","affiliation":[{"name":"1Department of Peptide-Based Immunotherapy, University and University Hospital T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"2Institute for Cell Biology, Department of Immunology, University of T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"7Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4271-1498","authenticated-orcid":false,"given":"Sarah M.","family":"Schroeder","sequence":"additional","affiliation":[{"name":"1Department of Peptide-Based Immunotherapy, University and University Hospital T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"2Institute for Cell Biology, Department of Immunology, University of T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"12Department of Otorhinolaryngology, Head and Neck Surgery, University of T\u00fcbingen, T\u00fcbingen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max-Felix","family":"H\u00e4ring","sequence":"additional","affiliation":[{"name":"1Department of Peptide-Based Immunotherapy, University and University Hospital T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"2Institute for Cell Biology, Department of Immunology, University of T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"7Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0612-9932","authenticated-orcid":false,"given":"Andreas","family":"Schlosser","sequence":"additional","affiliation":[{"name":"13Rudolf-Virchow-Zentrum, University W\u00fcrzburg, W\u00fcrzburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2780-2981","authenticated-orcid":false,"given":"Johannes","family":"Schetelig","sequence":"additional","affiliation":[{"name":"10Department of Medicine I, University Hospital of Dresden, Dresden, Germany."},{"name":"14German Bone Marrow Donor Center (DKMS), Clinical Trials Unit, Dresden, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3417-6736","authenticated-orcid":false,"given":"Marc","family":"Schmitz","sequence":"additional","affiliation":[{"name":"15Institute of Immunology, Faculty of Medicine Carl Gustav Carus, Technische Universit\u00e4t Dresden, Dresden, Germany."},{"name":"16National Center for Tumor Diseases (NCT), University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden, Dresden, Germany."},{"name":"17German Cancer Consortium (DKTK), partner site Dresden, and German Cancer Research Center (DKFZ), Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3670-0602","authenticated-orcid":false,"given":"Melanie","family":"Boerries","sequence":"additional","affiliation":[{"name":"9Faculty of Medicine, Medical Center, Institute of Medical Bioinformatics and Systems Medicine (IBSM), University of Freiburg, Germany."},{"name":"18Comprehensive Cancer Center Freiburg (CCCF), Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany."},{"name":"19German Cancer Consortium (DKTK), Partner Site, Freiburg, and German Cancer Research Center (DKFZ), Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7502-0431","authenticated-orcid":false,"given":"Natalie","family":"K\u00f6hler","sequence":"additional","affiliation":[{"name":"5Department of Medicine I, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany."},{"name":"20Centre for Integrative Biological Signalling Studies (CIBSS), University of Freiburg, Freiburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5442-2805","authenticated-orcid":false,"given":"Claudia","family":"Lengerke","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"8Department of Biomedicine, University of Basel and University Hospital Basel, Basel, Switzerland."},{"name":"21Clinic for Hematology, University of Basel and University Hospital Basel, Basel, Switzerland."},{"name":"22German Cancer Consortium (DKTK), DKFZ partner site T\u00fcbingen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5814-0984","authenticated-orcid":false,"given":"Ravindra","family":"Majeti","sequence":"additional","affiliation":[{"name":"6Institute for Stem Cell Biology and Regenerative Medicine and the Ludwig Cancer Center, Stanford University School of Medicine, Stanford, California."},{"name":"23Division of Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9077-7467","authenticated-orcid":false,"given":"Irving L.","family":"Weissman","sequence":"additional","affiliation":[{"name":"6Institute for Stem Cell Biology and Regenerative Medicine and the Ludwig Cancer Center, Stanford University School of Medicine, Stanford, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Georg","family":"Rammensee","sequence":"additional","affiliation":[{"name":"2Institute for Cell Biology, Department of Immunology, University of T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"3Cluster of Excellence iFIT (EXC2180) \u201cImage-Guided and Functionally Instructed Tumor Therapies\u201d, University of T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"22German Cancer Consortium (DKTK), DKFZ partner site T\u00fcbingen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6404-7391","authenticated-orcid":false,"given":"Juliane S.","family":"Walz","sequence":"additional","affiliation":[{"name":"1Department of Peptide-Based Immunotherapy, University and University Hospital T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"2Institute for Cell Biology, Department of Immunology, University of T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"3Cluster of Excellence iFIT (EXC2180) \u201cImage-Guided and Functionally Instructed Tumor Therapies\u201d, University of T\u00fcbingen, T\u00fcbingen, Germany."},{"name":"4Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital T\u00fcbingen, T\u00fcbingen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2023,10,17]]},"reference":[{"key":"2024012514521916700_bib1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nature22993","article-title":"Tracing the origins of relapse in acute myeloid leukaemia to stem cells","volume":"547","author":"Shlush","year":"2017","journal-title":"Nature"},{"key":"2024012514521916700_bib2","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/nm.2415","article-title":"Stem cell gene expression programs influence clinical outcome in human leukemia","volume":"17","author":"Eppert","year":"2011","journal-title":"Nat Med"},{"key":"2024012514521916700_bib3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J"},{"key":"2024012514521916700_bib4","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1182\/blood-2008-03-077974","article-title":"Graft-versus-leukemia effects of transplantation and donor lymphocytes","volume":"112","author":"Kolb","year":"2008","journal-title":"Blood"},{"key":"2024012514521916700_bib5","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"2024012514521916700_bib6","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"2024012514521916700_bib7","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"2024012514521916700_bib8","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/Phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"Von Stackelberg","year":"2016","journal-title":"J Clin Oncol"},{"key":"2024012514521916700_bib9","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1038\/s41375-021-01253-x","article-title":"T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments","volume":"35","author":"Daver","year":"2021","journal-title":"Leukemia"},{"key":"2024012514521916700_bib10","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.stem.2022.04.007","article-title":"Antigen presentation safeguards the integrity of the hematopoietic stem cell pool","volume":"29","author":"Hern\u00e1ndez-Malmierca","year":"2022","journal-title":"Cell Stem Cell"},{"key":"2024012514521916700_bib11","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00262-014-1551-x","article-title":"Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine","volume":"63","author":"Hu","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"2024012514521916700_bib12","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1002\/eji.1830191209","article-title":"Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells","volume":"19","author":"Panina-Bordignon","year":"1989","journal-title":"Eur J Immunol"},{"key":"2024012514521916700_bib13","doi-asserted-by":"crossref","first-page":"13404","DOI":"10.1038\/ncomms13404","article-title":"Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry","volume":"7","author":"Bassani-Sternberg","year":"2016","journal-title":"Nat Commun"},{"key":"2024012514521916700_bib14","doi-asserted-by":"crossref","first-page":"6401","DOI":"10.1038\/s41467-022-33746-3","article-title":"The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma","volume":"13","author":"Bauer","year":"2022","journal-title":"Nat Commun"},{"key":"2024012514521916700_bib15","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/s41467-020-14968-9","article-title":"Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes","volume":"11","author":"Chong","year":"2020","journal-title":"Nat Commun"},{"key":"2024012514521916700_bib16","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41587-021-01021-3","article-title":"Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer","volume":"40","author":"Ouspenskaia","year":"2021","journal-title":"Nat Biotechnol"},{"key":"2024012514521916700_bib17","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1158\/2326-6066.CIR-22-0621","article-title":"The immunopeptidome from a genomic perspective: Establishing the non-canonical landscape of MHC class I-associated peptides","volume":"11","author":"Bedran","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"2024012514521916700_bib18","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00018-022-04145-0","article-title":"Upstream open reading frames regulate translation of cancer-associated transcripts and encode HLA-presented immunogenic tumor antigens","volume":"79","author":"Nelde","year":"2022","journal-title":"Cell Mol Life Sci"},{"key":"2024012514521916700_bib19","doi-asserted-by":"crossref","first-page":"6031","DOI":"10.3390\/cancers14246031","article-title":"The emerging role of uORF-Encoded uPeptides and HLA uLigands in cellular and tumor biology","volume":"14","author":"J\u00fcrgens","year":"2022","journal-title":"Cancers"},{"key":"2024012514521916700_bib20","doi-asserted-by":"crossref","first-page":"e003404","DOI":"10.1136\/jitc-2021-003404","article-title":"Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors","volume":"9","author":"Marcu","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2024012514521916700_bib21","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s00262-020-02519-6","article-title":"Cancer testis antigen Cyclin A1 harbors several HLA-A*02:01-restricted T cell epitopes, which are presented and recognized in vivo","volume":"69","author":"Teck","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"2024012514521916700_bib22","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1182\/blood-2015-04-640532","article-title":"The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy","volume":"126","author":"Walz","year":"2015","journal-title":"Blood"},{"key":"2024012514521916700_bib23","doi-asserted-by":"crossref","first-page":"E9942","DOI":"10.1073\/pnas.1707658114","article-title":"The immunopeptidomic landscape of ovarian carcinomas","volume":"114","author":"Schuster","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024012514521916700_bib24","doi-asserted-by":"crossref","first-page":"705974","DOI":"10.3389\/fimmu.2021.705974","article-title":"Immunopeptidomics-guided warehouse design for peptide-based immunotherapy in chronic lymphocytic leukemia","volume":"12","author":"Nelde","year":"2021","journal-title":"Front Immunol"},{"key":"2024012514521916700_bib25","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1182\/blood-2018-07-866830","article-title":"The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy","volume":"133","author":"Bilich","year":"2019","journal-title":"Blood"},{"key":"2024012514521916700_bib26","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nm0797-730","article-title":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell","volume":"3","author":"Bonnet","year":"1997","journal-title":"Nat Med"},{"key":"2024012514521916700_bib27","doi-asserted-by":"crossref","first-page":"e002071","DOI":"10.1136\/jitc-2020-002071","article-title":"HLA Ligand Atlas: A benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy","volume":"9","author":"Marcu","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2024012514521916700_bib28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2105-7-153","article-title":"Predicting population coverage of T-cell epitope-based diagnostics and vaccines","volume":"7","author":"Bui","year":"2006","journal-title":"BMC Bioinform"},{"key":"2024012514521916700_bib29","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.3389\/fimmu.2017.01367","article-title":"Hotspots\u201d of antigen presentation revealed by human leukocyte antigen ligandomics for neoantigen prioritization","volume":"8","author":"M\u00fcller","year":"2017","journal-title":"Front Immunol"},{"key":"2024012514521916700_bib30","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2326-6066.CIR-19-0886","article-title":"Identification of the cryptic HLA-I immunopeptidome","volume":"8","author":"Erhard","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"2024012514521916700_bib31","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"2024012514521916700_bib32","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N Engl J Med"},{"key":"2024012514521916700_bib33","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nature14001","article-title":"Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing","volume":"515","author":"Yadav","year":"2014","journal-title":"Nature"},{"key":"2024012514521916700_bib34","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/imm.12936","article-title":"Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry","volume":"154","author":"Freudenmann","year":"2018","journal-title":"Immunology"},{"key":"2024012514521916700_bib35","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.1200\/JCO.2012.47.7521","article-title":"Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma","volume":"31","author":"van Rooij","year":"2013","journal-title":"J Clin Oncol"},{"key":"2024012514521916700_bib36","doi-asserted-by":"crossref","first-page":"5409","DOI":"10.3390\/molecules25225409","article-title":"Critical review of existing MHC I immunopeptidome isolation methods","volume":"25","author":"Kuznetsov","year":"2020","journal-title":"Molecules"},{"key":"2024012514521916700_bib37","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1021\/acs.jproteome.0c00386","article-title":"Mild acid elution and MHC immunoaffinity chromatography reveal similar albeit not identical profiles of the HLA class I immunopeptidome","volume":"20","author":"Sturm","year":"2021","journal-title":"J Proteome Res"},{"key":"2024012514521916700_bib38","doi-asserted-by":"crossref","first-page":"e06722","DOI":"10.7554\/eLife.06722","article-title":"Quality control of transcription start site selection by nonsense-mediated-mRNA decay","volume":"4","author":"Malabat","year":"2015","journal-title":"eLife"},{"key":"2024012514521916700_bib39","doi-asserted-by":"crossref","first-page":"6928","DOI":"10.4049\/jimmunol.176.11.6928","article-title":"Epitopes derived by incidental translational frameshifting give rise to a protective CTL response","volume":"176","author":"Zook","year":"2006","journal-title":"J Immunol"},{"key":"2024012514521916700_bib40","doi-asserted-by":"crossref","first-page":"e03528","DOI":"10.7554\/eLife.03528","article-title":"Extensive translation of small open reading frames revealed by poly-ribo-seq","volume":"3","author":"Aspden","year":"2014","journal-title":"eLife"},{"key":"2024012514521916700_bib41","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/nbt.4239","article-title":"Intron retention is a source of neoepitopes in cancer","volume":"36","author":"Smart","year":"2018","journal-title":"Nat Biotechnol"},{"key":"2024012514521916700_bib42","doi-asserted-by":"crossref","first-page":"aad3867","DOI":"10.1126\/science.aad3867","article-title":"Translation from the 5\u2019 untranslated region shapes the integrated stress response","volume":"351","author":"Starck","year":"2016","journal-title":"Science"},{"key":"2024012514521916700_bib43","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1084\/jem.184.4.1319","article-title":"Ribosomal scanning past the primary initiation codon as a mechanism for expression of CTL epitopes encoded in alternative reading frames","volume":"184","author":"Bullock","year":"1996","journal-title":"J Exp Med"},{"key":"2024012514521916700_bib44","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/stem.5530160810","article-title":"Maturation hierarchy of leukemic stem cells","volume":"16","author":"L\u00f6wenberg","year":"1998","journal-title":"Stem Cells"},{"key":"2024012514521916700_bib45","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1056\/NEJM199909303411407","article-title":"Acute myeloid leukemia","volume":"341","author":"L\u00f6wenberg","year":"1999","journal-title":"N Engl J Med"},{"key":"2024012514521916700_bib46","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/sj.leu.2402446","article-title":"Unique molecular and cellular features of acute myelogenous leukemia stem cells","volume":"16","author":"Jordan","year":"2002","journal-title":"Leukemia"},{"key":"2024012514521916700_bib47","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","article-title":"Immune escape of relapsed AML cells after allogeneic transplantation","volume":"379","author":"Christopher","year":"2018","journal-title":"N Engl J Med"},{"key":"2024012514521916700_bib48","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1056\/NEJMoa0811036","article-title":"Loss of Mismatched HLA in leukemia after stem-cell transplantation","volume":"361","author":"Vago","year":"2009","journal-title":"N Engl J Med"},{"key":"2024012514521916700_bib49","first-page":"413","article-title":"CD4+ T lymphocytes: a critical component of antitumor immunity","volume":"23","author":"Ostrand-Rosenberg","year":"2005","journal-title":"Cancer Invest"},{"key":"2024012514521916700_bib50","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"2024012514521916700_bib51","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"2024012514521916700_bib52","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41416-019-0531-5","article-title":"Distinct prognostic value of circulating anti-telomerase CD4+ Th1 immunity and exhausted PD-1+\/TIM-3+ T cells in lung cancer","volume":"121","author":"Laheurte","year":"2019","journal-title":"Br J Cancer"},{"key":"2024012514521916700_bib53","doi-asserted-by":"crossref","first-page":"e23651","DOI":"10.1371\/journal.pone.0023651","article-title":"Split T cell tolerance against a self\/tumor antigen: spontaneous CD4+ but Not CD8+ T cell responses against p53 in cancer patients and healthy donors","volume":"6","author":"Tsuji","year":"2011","journal-title":"PLoS One"},{"key":"2024012514521916700_bib54","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.3390\/cancers14092260","article-title":"HLA-DR presentation of the tumor antigen MSLN associates with clinical outcome of ovarian cancer patients","volume":"14","author":"Tegeler","year":"2022","journal-title":"Cancers"},{"key":"2024012514521916700_bib55","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1158\/1078-0432.CCR-11-3185","article-title":"Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response","volume":"18","author":"Godet","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2024012514521916700_bib56","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","article-title":"Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation","volume":"25","author":"Toffalori","year":"2019","journal-title":"Nat Med"},{"key":"2024012514521916700_bib57","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41586-018-0810-y","article-title":"Actively personalized vaccination trial for newly diagnosed glioblastoma","volume":"565","author":"Hilf","year":"2019","journal-title":"Nature"},{"key":"2024012514521916700_bib58","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/nm.2883","article-title":"Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival","volume":"18","author":"Walter","year":"2012","journal-title":"Nat Med"},{"key":"2024012514521916700_bib59","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.eururo.2015.12.050","article-title":"A Phase 2 randomized controlled trial of personalized peptide vaccine immunotherapy with low-dose dexamethasone versus dexamethasone alone in chemotherapy-naive castration-resistant prostate cancer","volume":"70","author":"Yoshimura","year":"2016","journal-title":"Eur Urol"},{"key":"2024012514521916700_bib60","article-title":"Evaluation of safety, immunogenicity, and preliminary efficacy of PolyPEPI1018 off-the-shelf vaccine with fluoropyrimidine\/bevacizumab maintenance therapy in metastatic colorectal cancer (mCRC) patients","volume":"8","author":"Hubbard","year":"2020","journal-title":"J Clin Oncol"},{"key":"2024012514521916700_bib61","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/s40425-019-0796-5","article-title":"A new synthetic toll-like receptor 1\/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer","volume":"7","author":"Rammensee","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2024012514521916700_bib62","doi-asserted-by":"crossref","first-page":"854","DOI":"10.3324\/haematol.2016.153528","article-title":"Long-term observation reveals high-frequency engraftment of human acute myeloid leukemia in immunodeficient mice","volume":"102","author":"Paczulla","year":"2017","journal-title":"Haematologica"},{"key":"2024012514521916700_bib63","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/978-1-4939-9450-2_10","article-title":"Purification and identification of naturally presented MHC class I and II ligands","volume":"1988","author":"Nelde","year":"2019","journal-title":"Methods Mol Biol"},{"key":"2024012514521916700_bib64","doi-asserted-by":"crossref","first-page":"E116","DOI":"10.1073\/pnas.1416389112","article-title":"HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL)","volume":"112","author":"Kowalewski","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024012514521916700_bib65","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/1044-0305(94)80016-2","article-title":"An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database","volume":"5","author":"Eng","year":"1994","journal-title":"J Am Soc Mass Spectrom"},{"key":"2024012514521916700_bib66","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/nmeth1113","article-title":"Semi-supervised learning for peptide identification from shotgun proteomics datasets","volume":"4","author":"K\u00e4ll","year":"2007","journal-title":"Nat Methods"},{"key":"2024012514521916700_bib67","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13073-016-0288-x","article-title":"NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets","volume":"8","author":"Nielsen","year":"2016","journal-title":"Genome Med"},{"key":"2024012514521916700_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00251-008-0341-z","article-title":"NetMHCpan, a method for MHC class I binding prediction beyond humans","volume":"61","author":"Hoof","year":"2009","journal-title":"Immunogenetics"},{"key":"2024012514521916700_bib69","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s002510050595","article-title":"SYFPEITHI: database for MHC ligands and peptide motifs","volume":"50","author":"Rammensee","year":"1999","journal-title":"Immunogenetics"},{"key":"2024012514521916700_bib70","doi-asserted-by":"crossref","first-page":"D777","DOI":"10.1093\/nar\/gkw1121","article-title":"COSMIC: somatic cancer genetics at high-resolution","volume":"45","author":"Forbes","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"2024012514521916700_bib71","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"N Engl J Med"},{"key":"2024012514521916700_bib72","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nature11016","article-title":"Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia","volume":"485","author":"Smith","year":"2012","journal-title":"Nature"},{"key":"2024012514521916700_bib73","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood-2013-01-476473","article-title":"Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia","volume":"122","author":"Opatz","year":"2013","journal-title":"Blood"},{"key":"2024012514521916700_bib74","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2007-05-091215","article-title":"Prognostic relevance of FLT3-TKD mutations in AML: the combination matters\u2013an analysis of 3082 patients","volume":"111","author":"Bacher","year":"2008","journal-title":"Blood"},{"key":"2024012514521916700_bib75","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","article-title":"Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis","volume":"99","author":"Thiede","year":"2002","journal-title":"Blood"},{"key":"2024012514521916700_bib76","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2006-10-053181","article-title":"Arginine 595 is duplicated in patients with acute leukemias carrying internal tandem duplications of FLT3 and modulates its transforming potential","volume":"110","author":"Vempati","year":"2007","journal-title":"Blood"},{"key":"2024012514521916700_bib77","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1182\/blood.V97.8.2434","article-title":"Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies","volume":"97","author":"Yamamoto","year":"2001","journal-title":"Blood"},{"key":"2024012514521916700_bib78","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1038\/ncomms2610","article-title":"Mouse urinary peptides provide a molecular basis for genotype discrimination by nasal sensory neurons","volume":"4","author":"Sturm","year":"2013","journal-title":"Nat Commun"},{"key":"2024012514521916700_bib79","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1074\/mcp.O113.036475","article-title":"Conserved peptide fragmentation as a benchmarking tool for mass spectrometers and a discriminating feature for targeted proteomics","volume":"13","author":"Toprak","year":"2014","journal-title":"Mol Cell Proteomics"},{"key":"2024012514521916700_bib80","doi-asserted-by":"crossref","first-page":"M111.010587","DOI":"10.1074\/mcp.M111.010587","article-title":"PEAKS DB: de novo sequencing assisted database search for sensitive and accurate peptide identification","volume":"11","author":"Zhang","year":"2012","journal-title":"Mol Cell Proteomics"},{"key":"2024012514521916700_bib81","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/leu.2014.233","article-title":"Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy","volume":"29","author":"Berlin","year":"2015","journal-title":"Leukemia"},{"key":"2024012514521916700_bib82","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/ijc.26365","article-title":"Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients","volume":"131","author":"Widenmeyer","year":"2012","journal-title":"Int J Cancer"},{"key":"2024012514521916700_bib83","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1126\/science.274.5284.94","article-title":"Phenotypic analysis of antigen-specific T lymphocytes","volume":"274","author":"Altman","year":"1996","journal-title":"Science"},{"key":"2024012514521916700_bib84","doi-asserted-by":"crossref","first-page":"4974","DOI":"10.4049\/jimmunol.171.10.4974","article-title":"Cutting edge: predetermined avidity of human CD8 T cells expanded on calibrated MHC\/anti-CD28-coated microspheres","volume":"171","author":"Walter","year":"2003","journal-title":"J Immunol"},{"key":"2024012514521916700_bib85","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s00262-013-1454-2","article-title":"Identification of HLA ligands and T-cell epitopes for immunotherapy of lung cancer","volume":"62","author":"Neumann","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"2024012514521916700_bib86","first-page":"2750","article-title":"HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy","volume":"126","author":"Nelde","year":"2017","journal-title":"Oncoimmunology"},{"key":"2024012514521916700_bib87","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jim.2003.10.017","article-title":"The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo","volume":"285","author":"Hermans","year":"2004","journal-title":"J Immunol Methods"},{"key":"2024012514521916700_bib88","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1093\/bioinformatics\/btaa611","article-title":"Scirpy: a Scanpy extension for analyzing single-cell T-cell receptor-sequencing data","volume":"36","author":"Sturm","year":"2020","journal-title":"Bioinformatics"},{"key":"2024012514521916700_bib89","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13059-017-1382-0","article-title":"SCANPY: Large-scale single-cell gene expression data analysis","volume":"19","author":"Wolf","year":"2018","journal-title":"Genome Biol"},{"key":"2024012514521916700_bib90","first-page":"418","article-title":"Bringing UMAP closer to the speed of light with GPU acceleration","volume-title":"Proceedings of the AAAI Conference on Artificial Intelligence","author":"Nolet"},{"key":"2024012514521916700_bib91","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1038\/s41598-019-41695-z","article-title":"From Louvain to Leiden: guaranteeing well-connected communities","volume":"26","author":"Traag","year":"2019","journal-title":"Sci Rep"},{"key":"2024012514521916700_bib92","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1186\/1471-2164-9-488","article-title":"BioVenn - a web application for the comparison and visualization of biological lists using area-proportional Venn diagrams","volume":"9","author":"Hulsen","year":"2008","journal-title":"BMC Genomics"},{"key":"2024012514521916700_bib93","doi-asserted-by":"crossref","first-page":"D442","DOI":"10.1093\/nar\/gky1106","article-title":"The PRIDE database and related tools and resources in 2019: Improving support for quantification data","volume":"47","author":"Perez-Riverol","year":"2019","journal-title":"Nucleic Acids Res"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-23-0020\/3372923\/bcd-23-0020.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/4\/6\/468\/3408419\/468.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/4\/6\/468\/3408419\/468.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T09:54:44Z","timestamp":1706176484000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/4\/6\/468\/729757\/Immune-Surveillance-of-Acute-Myeloid-Leukemia-Is"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,17]]},"references-count":93,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,10,17]]},"published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-23-0020","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.c.6908394","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.c.6908394.v2","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.c.6908394.v1","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2643-3230.25062172","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24473823","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24473820","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062169.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062169","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062172.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24473823.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24473820.v1","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,17]]}}}